Table 2.

The Various Clinical and Therapeutic Particularities of PMF According to JAK2 or CALR Molecular Subtypes.

JAK2V617F-mutated ET CALR-mutated ET
Age Older Younger
Blood counts Hemoglobin Higher Lower
Platelet Lower Higher
White blood count Higher Lower
Overall survival Longer, may be restricted only to patients with type 1 CALR mutations
Treatment implications Stem cell transplant should be considered not only for DIPSS-plus high-risk myelofibrosis but also for any-risk disease with CALR(−)/ASXL1(+) mutational status
RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2014 October; 5(4): e0035. ISSN: 2076-9172
Published online 2014 October 29. doi: 10.5041/RMMJ.10169.